Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00698464 |
Recruitment Status :
Completed
First Posted : June 17, 2008
Last Update Posted : December 21, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatic Cirrhosis Alcoholism | Drug: Pasireotide | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 34 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | A Phase I, Open-label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function |
Study Start Date : | July 2008 |
Actual Primary Completion Date : | April 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: Pasireotide |
Drug: Pasireotide
Single subcutaneous injection of 600 µg of Pasireotide. |
- Determination of the pharmacokinetic profile of single dose of pasireotide s.c. injection. [ Time Frame: 5 days ]
- Determination of the safety after a single dose of pasireotide s.c. injection [ Time Frame: 5 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Common Inclusion criteria for all subjects:
- Male or female subjects between 18 and 75 years of age, inclusive.
- Vital signs at screening and baseline which are within normal ranges.
- Subjects must have a BMI between 20 kg/m2 and 30 kg/m2.
Inclusion Criteria for cohort 1:
• Generally healthy subjects as determined by past medical history, physical examination, vital signs, electrocardiogram and standard laboratory tests at screening.
Inclusion Criteria for cohort 2-4:
- Subjects with confirmed cirrhosis by at least one of the following criteria:
- Histologically by prior liver biopsy showing cirrhosis.
- Clinically by physical examination, and/or laboratory data, and/or liver imaging, and/or endoscopic findings.
Exclusion criteria:
Common Exclusion criteria for all subjects:
- Donation or loss of 400 mL or more of blood within eight weeks prior to dosing.
- Subjects with additional active malignant disease within the last five years (with the exception of non-melanoma skin cancers that were not metastatic and have been treated curatively).
- Subjects with abnormal clinical laboratory values (except the clinical laboratory values linked to hepatic dysfunction).
- Any surgical or medical condition that may interfere with the conduct of the study, may jeopardize the subject in case of participation in the study or may significantly alter the absorption, distribution, metabolism or excretion of drugs.
- History of immunocompromise, including a positive HIV test result (ELISA and Western blot). A HIV test will not be required; however, previous medical history will be reviewed
- Female subjects who are pregnant (positive pregnancy test at screening or at baseline) or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control.
Exclusion Criteria for cohort 1:
- Clinical evidence of liver disease or liver injury as indicated by abnormal liver function tests.
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result (antibody positive subjects will be allowed if non-viremic).
Exclusion Criteria for cohort 2-4:
- Symptoms or history of encephalopathy (Stage III or worse) within three months prior to dosing.
- Clinical evidence of severe ascites. Exclusion criteria
Common Exclusion criteria for all subjects:
- Donation or loss of 400 mL or more of blood within eight weeks prior to dosing.
- Subjects with additional active malignant disease within the last five years (with the exception of non-melanoma skin cancers that were not metastatic and have been treated curatively).
- Subjects with abnormal clinical laboratory values (except the clinical laboratory values linked to hepatic dysfunction).
- Any surgical or medical condition that may interfere with the conduct of the study, may jeopardize the subject in case of participation in the study or may significantly alter the absorption, distribution, metabolism or excretion of drugs.
- History of immunocompromise, including a positive HIV test result (ELISA and Western blot). A HIV test will not be required; however, previous medical history will be reviewed
- Female subjects who are pregnant (positive pregnancy test at screening or at baseline) or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control.
Exclusion Criteria for cohort 1:
- Clinical evidence of liver disease or liver injury as indicated by abnormal liver function tests.
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result (antibody positive subjects will be allowed if non-viremic).
Exclusion Criteria for cohort 2-4:
- Symptoms or history of encephalopathy (Stage III or worse) within three months prior to dosing.
- Clinical evidence of severe ascites.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00698464
United States, Virginia | |
McGuire Research Institute VAMC | |
Richmond, Virginia, United States, 23249 | |
Belgium | |
Universite Catholique de Louvain | |
Brussels, Belgium | |
Germany | |
Novartis Investigative site | |
Berlin, Germany | |
South Africa | |
Novartis Investigative Site | |
George, South Africa |
Study Director: | Novartis Pharmaceuticlas | Novartis Pharmaceuticlas |
Publications of Results:
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00698464 |
Other Study ID Numbers: |
CSOM230B2114 |
First Posted: | June 17, 2008 Key Record Dates |
Last Update Posted: | December 21, 2020 |
Last Verified: | November 2016 |
Pasireotide PK profile, Single dose Pasireotide subcutaneous injection |
Safety Mild hepatic impaired patients Moderate hepatic impaired patients Severe hepatic impaired patients |
Liver Cirrhosis Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |
Liver Diseases Digestive System Diseases Pasireotide Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |